Go back

Peter Luu

Senior Vice President

Mr. Luu became a member of Sakura Finetek Management team in April 2016 following the acquisition of Genemed Biotechnologies, Inc. by Sakura Finetek. From 2005 to 2015, he served as the President of Genemed during which he negotiated and supported a major manufacturing contract with Roche Molecular Systems and for immunohistochemistry product development. Mr. Luu joined the founders of Zymed Laboratories Inc. in 1980 and held the position of Vice President of Operations. During this period, he transformed the company from a research reagent oriented organization to an in-vitro diagnostics manufacturing firm.  Zymed was acquired by Invitrogen in 2005 for its IHC and HER-2 genetic probe diagnostic products. Mr. Luu started his career as a Research Scientist at Gastroenterology Research Unit, Department of Medicine of University of California San Francisco. He has patented an immunostaining process for mouse antibody on mouse tissue in 1999.
With an undergraduate degree from University of California, Berkeley, Mr. Luu continued his education by completing a two-years Master Degree program in Medical Microbiology and two more years of the Ph.D. program in Experimental Pathology at University California, San Francisco.